Author

Maria Pitsouni

Institution: Quantum Leap Healthcare Collaborative

Observed institution: Quantum Leap Healthcare Collaborative

OpenAlex ID: A5026919282

Abstract GS5-03: Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

2023 · Claudine Isaacs, Rita Nanda, et al. · Cancer Research · 18

Abstract PD11-01: PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

2023 · Erica Stringer-Reasor, Rebecca A. Shatsky, et al. · Cancer Research · 3

Abstract GS5-04: Identification of symptoms that are associated with irAEs in the I-SPY clinical trial

2023 · Amrita Basu, Saumya Umashankar, et al. · Cancer Research · 2

Works count: 3

Citation count: 23

H-index: 2

I10-index: 1